Study type: In vivo/preclinical · Status: Verified against declared source
Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats.
PloS one · 2013
Study scale: Brains were collected from representative animals in each group, and immediately fixed in 10% phosphate-buffered formaldehyde.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Cerebrolysin (CBL), a mixture of several active peptide fragments and neurotrophic factors including brain-derived neurotrophic factor (BDNF), is currently used in the management of cognitive alterations in patients with dementia.
Methods
Not reported in the reviewed source.
Scale or participants
Brains were collected from representative animals in each group, and immediately fixed in 10% phosphate-buffered formaldehyde.
Key findings
Cerebrolysin (CBL), a mixture of several active peptide fragments and neurotrophic factors including brain-derived neurotrophic factor (BDNF), is currently used in the management of cognitive alterations in patients with dementia.
Limitations and uncertainty
Cerebrolysin (CBL), a mixture of several active peptide fragments and neurotrophic factors including brain-derived neurotrophic factor (BDNF), is currently used in the management of cognitive alterations in patients with dementia.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.